Brief: Cumberland Pharmaceuticals Reports 17% Revenue Growth For Full Year 2022
07/03/2023 21:43
March 7 (Reuters) - Cumberland Pharmaceuticals Inc CPIX.O :
* CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR
FULL
YEAR 2022
* CUMBERLAND PHARMACEUTICALS INC - QTRLY LOSS PER SHARE FROM
CONTINUING OPERATIONS DILUTED $0.17
* CUMBERLAND PHARMACEUTICALS INC - QTRLY ADJUSTED LOSS $0.05
PER
SHARE
Source text for Eikon: ID:nPn9kKNfBa
Further company coverage: CPIX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cumberland Pharmaceuticals
See all newsBrief: Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results
Cumberland Pharmaceuticals Q2 loss widens after Apotex transaction
Brief: Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share
Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln
NASDAQ RESUMED AT 09:38 AM